Inventor
LOWY ISRAEL
US32 patents
⚠️ This page may combine multiple inventors who share the name “LOWY ISRAEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
18 patentsUS8980268B2Mar 17, 2015
Methods for treating cancer by administering an anti-Ang-2 antibody
REGENERON PHARMA16 citations92
US9968674B2May 15, 2018
Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody
REGENERON PHARMA10 citations84
US9963501B2May 8, 2018
B cell lineage based immunogen design with humanized animals
REGENERON PHARMA6 citations82
US11919965B2Mar 5, 2024
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
REGENERON PHARMA7 citations81
US12054557B2Aug 6, 2024
Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer
REGENERON PHARMA4 citations72
US10662244B2May 26, 2020
Methods for tumor treatment using CD3XCD20 bispecific antibody
REGENERON PHARMA2 citations72
US11926668B2Mar 12, 2024
Anti-PD-1 antibodies for treatment of lung cancer
REGENERON PHARMA3 citations70
US11292842B2Apr 5, 2022
Anti-PD-1 antibodies for treatment of lung cancer
REGENERON PHARMA5 citations68
US10457725B2Oct 29, 2019
Methods of treating skin cancer by administering a PD-1 inhibitor
REGENERON PHARMA2 citations68
US11590223B2Feb 28, 2023
Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
REGENERON PHARMA4 citations66
US10626168B2Apr 21, 2020
B cell lineage based immunogen design with humanized animals
REGENERON PHARMA1 citations60
US12473364B2Nov 18, 2025
Intralesional administration of PD-1 inhibitors for treating skin cancer
REGENERON PHARMA0 citations58
US11505600B2Nov 22, 2022
Methods of treating skin cancer by administering a PD-1 inhibitor
REGENERON PHARMA1 citations58
US11439683B2Sep 13, 2022
Anti-angiogenic therapy of metastatic colorectal cancer
REGENERON PHARMA0 citations57
US10532096B2Jan 14, 2020
Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
REGENERON PHARMA0 citations52
US9926369B2Mar 27, 2018
Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody
REGENERON PHARMA0 citations52
US10525104B2Jan 7, 2020
Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
REGENERON PHARMA0 citations47
US9399674B2Jul 26, 2016
Human antibodies to Clostridium difficile toxins
REGENERON PHARMA1 citations46
MEDAREX INC
4 patentsUS7456264B2Nov 25, 2008
Human monoclonal antibodies against Bacillus anthracis protective antigen
MEDAREX INC88 citations96
US7465446B2Dec 16, 2008
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
MEDAREX INC52 citations94
US7744875B2Jun 29, 2010
Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease
MEDAREX INC16 citations91
US7611702B2Nov 3, 2009
TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
MEDAREX INC12 citations73
AMBROSINO DONNA M
3 patentsUS8257709B2Sep 4, 2012
Antibodies against Clostridium difficile toxins and uses thereof
AMBROSINO DONNA M22 citations90
US8236311B2Aug 7, 2012
Antibodies against clostridium difficile toxins and uses thereof
AMBROSINO DONNA M15 citations90
US8609111B2Dec 17, 2013
Antibodies against clostridium difficile toxins and uses thereof
AMBROSINO DONNA M4 citations71